Reading Time: 2 minutes
For me, Eli Lilly (LLY) remains one of the most exciting leader stocks in the healthcare sector following the recent rally. The approval of the weight loss pill Orforglipron (Foundayo) in China on November 12 opens up a new growth opportunity. Lilly is the first provider of an approved GLP-1 weight loss tablet there. Novo Nordisk has only submitted its Wegovy pill for approval so far. This provides an additional argument for my ongoing preference for Lilly over Novo. What I find particularly interesting is the analysis from Jefferies. On November...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
